ER、PR、C-erbB-2与抗肿瘤药物的敏感性关系研究
|
摘要
背景与目的
乳腺癌是威胁女性生命和健康的恶性疾病之一,乳腺癌术后化学治疗有效地改善了患者的预后,是乳腺癌综合治疗的重要措施,恶性肿瘤具有较强异质性,对各种化疗药物存在明显个体差异,肿瘤药敏试验通过检测癌细胞对化疗药物的敏感性,直接获得试验数据,指导临床个性化选择药物。由于肿瘤药敏试验开展的局限性,建立乳腺癌基因型与各种抗肿瘤药物的敏感性关系,间接根据肿瘤药敏指导临床选药,为乳腺癌个性化化疗提供了一种方法。
乳腺癌基因型分为Lumi nalA型：ER(+).PR(+).C-erbB-2(-), LuminalB型：ER(+).PR(+).C-erbB-2(+),Basal-like型：ER(-).PR(-).C-erbB-2(-)和ERBB2(+)型：ER(-).PR(-).C-erbB-2(+).目前,肿瘤药敏试验在乳腺癌药物选择方面进行过一些研究,但是尚无ER、PR、C-erbB-2与抗肿瘤药物的敏感性和化疗方案关系的类似研究。
ER是细胞高特异性糖蛋白,可与细胞配体紧密结合,较低数量的配体即可激活ER通路,产生作用。ER通过诱导雌激素作用的基因转录促使癌细胞增殖。
PR是雌激素作用的终产物,PR的合成须有雌激素启动,ER水平是影响PR表达的重要因素,其阳性程度越高,PR表达就越多,ER活性及其通路是PR表达的关键。
C-erbB-2是一种原癌基因,其在细胞生长因子信号传导通路及控制正常细胞生长和分裂中起决定性作用,生长因子与细胞表面C-erbB-2受体结合后,活化胞内酪氨酸蛋白激酶,引起酪氨酸自身磷酸化,进而引发瀑布式连锁反应,信号经细胞膜和细胞间质传至细胞核,激活C-erbB-2基因,增强细胞有丝分裂,调控细胞生长,促进肿瘤增殖及分化,其过度表达提示C-erbB-2基因无限扩增,进而引起C-erbB-2基因复制转录增加,从而导致C-erbB-2mRNA翻译水平提高和C-erbB-2受体合成增加及过表达,通过与配体结合,诱使信号传导通路激活,引发肿瘤细胞无限分裂和生长。C-erbB-2也是耐药基因,其阳性率越高,癌细胞耐药性越强,疗效越差。由于乳腺癌基因分型可更好地反映肿瘤的生物学行为,且其基因表型可影响化疗药物的敏感性,因此,通过肿瘤药敏试验建立ER、PR、C-erbB-2与抗肿瘤药物的敏感性关系,进而指导临床个性化选择药物,可使化学治疗更有针对性。
材料与方法
1标本
收集2008年7月至2009年12月在郑州大学第二附属医院乳腺科入院手术治疗的69例乳腺癌标本,术中经快速冰冻病理证实为乳腺癌,行乳腺癌根治术或保乳术后标本进一步常规病理检查,并检测ER、PR、C-erbB-2。肿块标本收集后,立即送到实验室进行如下处理,避免标本细菌污染,①在15ml培养管中用RMPI-1640培养液冲洗标本3次；②加含100U/ml青、链霉素的RMPI-1640培养液适量浸泡标本20min,完成上述处理后,在无菌原则下,剪碎标本,进行下步处理。
2研究方法
把标本制成单细胞悬液,检测细胞活性度和计数,调整细胞浓度,设立试验组、空白对照组和细胞对照组,各种药物稀释成试验用药液后,加药液于96孔细胞培养板上,培养四天后,加入0.5%MTT经过培养和溶解后,在酶标仪上检测吸光度值,计算各孔细胞抑制率。
3评价标准
以5PPC溶液浓度作为药物敏感性评价浓度,其评价标准为：高敏感组肿瘤细胞抑制率>50%,敏感组肿瘤细胞抑制率为30%-50%,耐药组肿瘤细胞抑制率<30%。
4统计学方法
本试验所有数据采用SPSS17.0统计软件进行处理,计量资料以均数±标准差(x±s)表示,进行方差齐性检验和正态性检验,符合条件多组比较采用单因素方差分析(one-way ANOVA),组间两两比较采用最小显著性差异(LSD)法,P<0.05为差异有统计学意义。
结果
氟尿嘧啶在ER(+)、PR(+)、C-erbB-2(-), ER(+)、PR(+)、C-erbB-2(+), ER(-)、PR(-)、C-erbB-2(-)和ER(-)、PR(-)、C-erbB-2(+)四组标本中,细胞抑制率没有体现出统计学差异(P>0.05),这可能与各组收集标本例数较少有关,甲氨喋呤在ER(+)、PR(+)、C-erbB-2(-)型细胞抑制率高于ER(+)、PR(+)、C-erbB-2(+)型,ER(-)、PR(-)、C-erbB-2(-)型和ER(-)、PR(-)、C-erbB-2(+)型(P<0.05)；阿霉素在ER(+)、PR(+)、C-erbB-2(-)型细胞抑制率高于ER(-)、PR(-)、C-erbB-2(-)和ER(-)、PR(-)、C-erbB-2(+)型(P<0.05)；表阿霉素在ER(+)、PR(+)、C-erbB-2(-)型细胞抑制率高于ER(-)、PR(-)、C-erbB-2(+)型(P<0.05)；紫杉醇在ER(+)、PR(+)、C-erbB-2(-)型细胞抑制率高于ER(+)、PR(+)、C-erbB-2(+)型,ER(-)、PR(-)、C-erbB-2(-)型和ER(-)、PR(-)、C-erbB-2(+)型(P<0.05)。
结论
1.乳腺癌基因型与化疗敏感性存在关系。ER(+)、PR(+)、C-erbB-2(-)、ER(+). PR(+)、C-erbB-2(+)和ER(-)、PR(-)、C-erbB-2(-)三型在各种抗肿瘤药物的细胞抑制率高低顺序一致：PTX>EPI>ADM>5-FU>MTX；ER(-)、PR(-)、C-erbB-2(+)型在各种抗肿瘤药物的细胞抑制率高低为：PTX>ADM>EPI> 5-FU>MTX。
2.不同基因型的乳腺癌对同一种化疗药的细胞抑制率不同,提示化疗的获益不同。紫杉醇、阿霉素、表阿霉素、氟尿嘧啶和甲氨蝶呤在ER(+)、PR(+)、C-erbB-2(-)型细胞抑制率均最高,在ER(-)、PR(-)、C-erbB-2(-)型细胞抑制率均最低。乳腺癌的化疗应考虑其基因型的不同,选择敏感药物,争取最大获益,实现乳腺癌治疗个体化。
Background and Objectives
Breast cancer is one of malignant disease which poses a great threat to women's life and health. Adjuvant chemotherapy for the treatment of breast cancer is an effective method in improving the prognosis, which is an important measure for comprehensive treatments for breast cancer. malignant tumors have strong heterogeneity. Various chemotherapy have obviously individual differences in medicines, The sensitivity assay for anticancer drugs may examine the sensitivity of cancer cells to chemotherapeutic agents, which can directly acquire experimental data. This can guide the application of drugs for clinical personalization. Due to the limitations of tumor chemosensitivity assay carried on, establishing relationships of breast cancer genotype and anticancer drugs, we can indirectly select medicines based on clinical cancer susceptibility, this can provides a way to personalized chemotherapy for breast cancer.
Genotype is divided into LuminalA of breast cancer:ER(+), PR(+), C-erbB-2 (-),and LuminalB:ER (+), PR (+), C-erbB-2 (+), Basal-like:ER (-), PR (-), C-erbB-2 (-) and ERBB2 (+):ER (-), PR (-), C-erbB-2 (+). At present, tumor chemosensitivity assay was carried on some study in breast cancer, but no related studies of ER, PR, C-erbB-2 and anticancer drugs sensitivity in chemotherapy for breast cancer.
ER can be closely integrated with the cell ligand, which is highly specific glycoprotein cells. A small quantity of ligand can activate ER pathway effectively. ER depend on estrogen effect to induce gene transcription and promote proliferation of tumor cells.
PR is end products, which can be affected by estrogen. Estrogen promotes the synthesis of PR. ER expression levels are important factors which affect PR expression, the higher the positive degree of ER, the more PR expression, activity and the pathway of ER is a key factor for PR expression.
C-erbB-2 is a proto-oncogene, which plays a decisive role in growth factor signaling pathways and controls normal cell growth and differentiation. Growth factors and C-erbB-2 receptor on the cell surface can activate intracellular tyrosine kinase, and then cause phosphorylation of tyrosine itself, which may keep triggering a cascade of chain reactions. The signals through the cell membrane and the stromal cells spreads into the nucleus, which activate C-erbB-2 gene, accelerate mitosis, regulate cell growth and promote the proliferation and differentiation of malignant tumor, its overexpression prompts C-erbB-2 gene amplification infinitely, and then promotes C-erbB-2 gene transcription, increases replication, and keeps enhancing C-erbB-2mRNA translation level and C-erbB-2 receptors synthesis and overexpression, this can induce signaling pathways activated through ligand binding, keep triggering the growth and differentiation of tumor cell infinitely. C-erbB-2 is also a drug-resisted gene. The higher the positive rate of C-erbB-2, the stronger the cancer cells resists. Because genotyping of breast cancer may affect the biological behavior of tumors and the sensitivity of chemotherapy. Therefore, depending on test of tumor susceptibility, establishing relationship of ER, PR, C-erbB-2 and the anti-tumor drugs, and then guided the selection of clinical personalized medicine. Chemotherapy will be more focused treatment.
Materials and Methods
1 Specimen
Breast surgical treatment of 69 hospitalized patients were collected from July 2008 to December 2009 at the Second Affiliated Hospital of Zhengzhou University. Intraoperative frozen section and routine pathological examination confirmed breast cancer after radical mastectomy or breast conserving surgery. We will detect ER, PR, C-erbB-2 simultaneously. Tumor specimens were immediately sent to the laboratory for the following treatment to avoid specimens contamination,①We use culture medium of RMPI-1640 to wash specimens three times in 15ml culture tubes;②We add with amount of RMPI-1640 involved 100U/ml penicillin and streptomycin to immerse specimens at twenty minutes, after completion of the deal, under the principle in sterile, clipping specimens to process the next step.
2 Research methods
The specimens were made into single cell suspension, then we examine cells degrees and counting, adjust the cell concentration, establish the experimental group, control group and cell control group. Various drugs are diluted to experimental liquids. We may add the liquids to 96 holes training board to cultivate specimens four days later, and add again 0.5% MTT cultivating and dissolved. We axamine absorbency in the microplate reader to calculate inhibiting rate of tumor cells in every hole.
3 Evaluation Criteria
5PPC solution serves as the concentration of drug sensitivity. Criteria of evaluation are that high sensitivity of tumor inhibiting rate is above 50%, sensitivity of tumor inhibiting rate is between 30%-50%, inhibiting rate of tumor cells of resistance is below 30%.
4 Statistic analysis
In this study, All the data were expressed by (x±s). The statistical software SSPS17.0 for windows was exploited to analyze data. Which was processed the test of homogeneity of variance and normality, Deviation and difference were compared using the one way ANOVA and LSD test between each group, The different significance is judged by P<0.05.
Results
The four specimens of ER(+), PR(+), C-erbB-2(-), ER(+), PR(+), C-erbB-2(+), ER(-), PR(-), C-erbB-2(-) and ER(-), PR(-), C-erbB-2(+) do not reflect the significant difference in fluorouracil(P>0.05). The ER(+), PR(+), C-erbB-2(-) have an advantage over ER(+), PR(+), C-erbB-2(+), ER(-), PR(-), C-erbB-2(-) and ER(-), PR(-), C-erbB-2(+) in methotrexate(P<0.05). The ER(+), PR(+), C-erbB-2(-) have an advantage over ER(-), PR(-), C-erbB-2(-) and ER(-), PR(-), C-erbB-2(+) in adriamycin(P<0.05); The ER(+), PR(+), C-erbB-2(-) have an advantage over ER(-), PR(-), C-erbB-2(+) in epirubicin (P<0.05). The ER(+), PR(+), C-erbB-2(-) have an advantage over ER(+), PR(+), C-erbB-2(+), ER(-), PR(-), C-erbB-2(-) and ER(-), PR(-), C-erbB-2(+) in paclitaxel(P<0.05).
Conclusions
1. The experiments shows that genotypes are correlate with sensitivity of chemotherapy in breast cancer. ER(+), PR(+), C-erbB-2(-), ER(+), PR(+), C-erbB-2(+) and ER(-), PR(-), C-erbB-2(-) three types of cells have the same orders in various inhibiting rates in anticancer drugs:PTX> EPI> ADM> 5-FU> MTX. ER(-), PR(-), C-erbB-2(+) cells has a different inhibiting effect on a variety of anticancer, its sequence follows as:PTX> ADM> EPI> 5-FU> MTX.
2. Different genotypes of breast cancer have different inhibiting rates to the same chemotherapeutic drug, which suggests that they have different chemotherapeutic benefit. Paclitaxel, doxorubicin, epirubicin, fluorouracil and methotrexate have the highest inhibiting effect in the ER(+), PR (+), C-erbB-2(-). All five drugs have the lowest inhibiting effect in the ER(-), PR(-), C-erbB-2(-). Based on the different genotypes, we choose sensitive drugs so as to obtain maximum benefit of treatment and achieve individualized treatment for breast cancer.
乳腺癌是威胁女性生命和健康的恶性疾病之一,乳腺癌术后化学治疗有效地改善了患者的预后,是乳腺癌综合治疗的重要措施,恶性肿瘤具有较强异质性,对各种化疗药物存在明显个体差异,肿瘤药敏试验通过检测癌细胞对化疗药物的敏感性,直接获得试验数据,指导临床个性化选择药物。由于肿瘤药敏试验开展的局限性,建立乳腺癌基因型与各种抗肿瘤药物的敏感性关系,间接根据肿瘤药敏指导临床选药,为乳腺癌个性化化疗提供了一种方法。
乳腺癌基因型分为Lumi nalA型：ER(+).PR(+).C-erbB-2(-), LuminalB型：ER(+).PR(+).C-erbB-2(+),Basal-like型：ER(-).PR(-).C-erbB-2(-)和ERBB2(+)型：ER(-).PR(-).C-erbB-2(+).目前,肿瘤药敏试验在乳腺癌药物选择方面进行过一些研究,但是尚无ER、PR、C-erbB-2与抗肿瘤药物的敏感性和化疗方案关系的类似研究。
ER是细胞高特异性糖蛋白,可与细胞配体紧密结合,较低数量的配体即可激活ER通路,产生作用。ER通过诱导雌激素作用的基因转录促使癌细胞增殖。
PR是雌激素作用的终产物,PR的合成须有雌激素启动,ER水平是影响PR表达的重要因素,其阳性程度越高,PR表达就越多,ER活性及其通路是PR表达的关键。
C-erbB-2是一种原癌基因,其在细胞生长因子信号传导通路及控制正常细胞生长和分裂中起决定性作用,生长因子与细胞表面C-erbB-2受体结合后,活化胞内酪氨酸蛋白激酶,引起酪氨酸自身磷酸化,进而引发瀑布式连锁反应,信号经细胞膜和细胞间质传至细胞核,激活C-erbB-2基因,增强细胞有丝分裂,调控细胞生长,促进肿瘤增殖及分化,其过度表达提示C-erbB-2基因无限扩增,进而引起C-erbB-2基因复制转录增加,从而导致C-erbB-2mRNA翻译水平提高和C-erbB-2受体合成增加及过表达,通过与配体结合,诱使信号传导通路激活,引发肿瘤细胞无限分裂和生长。C-erbB-2也是耐药基因,其阳性率越高,癌细胞耐药性越强,疗效越差。由于乳腺癌基因分型可更好地反映肿瘤的生物学行为,且其基因表型可影响化疗药物的敏感性,因此,通过肿瘤药敏试验建立ER、PR、C-erbB-2与抗肿瘤药物的敏感性关系,进而指导临床个性化选择药物,可使化学治疗更有针对性。
材料与方法
1标本
收集2008年7月至2009年12月在郑州大学第二附属医院乳腺科入院手术治疗的69例乳腺癌标本,术中经快速冰冻病理证实为乳腺癌,行乳腺癌根治术或保乳术后标本进一步常规病理检查,并检测ER、PR、C-erbB-2。肿块标本收集后,立即送到实验室进行如下处理,避免标本细菌污染,①在15ml培养管中用RMPI-1640培养液冲洗标本3次；②加含100U/ml青、链霉素的RMPI-1640培养液适量浸泡标本20min,完成上述处理后,在无菌原则下,剪碎标本,进行下步处理。
2研究方法
把标本制成单细胞悬液,检测细胞活性度和计数,调整细胞浓度,设立试验组、空白对照组和细胞对照组,各种药物稀释成试验用药液后,加药液于96孔细胞培养板上,培养四天后,加入0.5%MTT经过培养和溶解后,在酶标仪上检测吸光度值,计算各孔细胞抑制率。
3评价标准
以5PPC溶液浓度作为药物敏感性评价浓度,其评价标准为：高敏感组肿瘤细胞抑制率>50%,敏感组肿瘤细胞抑制率为30%-50%,耐药组肿瘤细胞抑制率<30%。
4统计学方法
本试验所有数据采用SPSS17.0统计软件进行处理,计量资料以均数±标准差(x±s)表示,进行方差齐性检验和正态性检验,符合条件多组比较采用单因素方差分析(one-way ANOVA),组间两两比较采用最小显著性差异(LSD)法,P<0.05为差异有统计学意义。
结果
氟尿嘧啶在ER(+)、PR(+)、C-erbB-2(-), ER(+)、PR(+)、C-erbB-2(+), ER(-)、PR(-)、C-erbB-2(-)和ER(-)、PR(-)、C-erbB-2(+)四组标本中,细胞抑制率没有体现出统计学差异(P>0.05),这可能与各组收集标本例数较少有关,甲氨喋呤在ER(+)、PR(+)、C-erbB-2(-)型细胞抑制率高于ER(+)、PR(+)、C-erbB-2(+)型,ER(-)、PR(-)、C-erbB-2(-)型和ER(-)、PR(-)、C-erbB-2(+)型(P<0.05)；阿霉素在ER(+)、PR(+)、C-erbB-2(-)型细胞抑制率高于ER(-)、PR(-)、C-erbB-2(-)和ER(-)、PR(-)、C-erbB-2(+)型(P<0.05)；表阿霉素在ER(+)、PR(+)、C-erbB-2(-)型细胞抑制率高于ER(-)、PR(-)、C-erbB-2(+)型(P<0.05)；紫杉醇在ER(+)、PR(+)、C-erbB-2(-)型细胞抑制率高于ER(+)、PR(+)、C-erbB-2(+)型,ER(-)、PR(-)、C-erbB-2(-)型和ER(-)、PR(-)、C-erbB-2(+)型(P<0.05)。
结论
1.乳腺癌基因型与化疗敏感性存在关系。ER(+)、PR(+)、C-erbB-2(-)、ER(+). PR(+)、C-erbB-2(+)和ER(-)、PR(-)、C-erbB-2(-)三型在各种抗肿瘤药物的细胞抑制率高低顺序一致：PTX>EPI>ADM>5-FU>MTX；ER(-)、PR(-)、C-erbB-2(+)型在各种抗肿瘤药物的细胞抑制率高低为：PTX>ADM>EPI> 5-FU>MTX。
2.不同基因型的乳腺癌对同一种化疗药的细胞抑制率不同,提示化疗的获益不同。紫杉醇、阿霉素、表阿霉素、氟尿嘧啶和甲氨蝶呤在ER(+)、PR(+)、C-erbB-2(-)型细胞抑制率均最高,在ER(-)、PR(-)、C-erbB-2(-)型细胞抑制率均最低。乳腺癌的化疗应考虑其基因型的不同,选择敏感药物,争取最大获益,实现乳腺癌治疗个体化。
Background and Objectives
Breast cancer is one of malignant disease which poses a great threat to women's life and health. Adjuvant chemotherapy for the treatment of breast cancer is an effective method in improving the prognosis, which is an important measure for comprehensive treatments for breast cancer. malignant tumors have strong heterogeneity. Various chemotherapy have obviously individual differences in medicines, The sensitivity assay for anticancer drugs may examine the sensitivity of cancer cells to chemotherapeutic agents, which can directly acquire experimental data. This can guide the application of drugs for clinical personalization. Due to the limitations of tumor chemosensitivity assay carried on, establishing relationships of breast cancer genotype and anticancer drugs, we can indirectly select medicines based on clinical cancer susceptibility, this can provides a way to personalized chemotherapy for breast cancer.
Genotype is divided into LuminalA of breast cancer:ER(+), PR(+), C-erbB-2 (-),and LuminalB:ER (+), PR (+), C-erbB-2 (+), Basal-like:ER (-), PR (-), C-erbB-2 (-) and ERBB2 (+):ER (-), PR (-), C-erbB-2 (+). At present, tumor chemosensitivity assay was carried on some study in breast cancer, but no related studies of ER, PR, C-erbB-2 and anticancer drugs sensitivity in chemotherapy for breast cancer.
ER can be closely integrated with the cell ligand, which is highly specific glycoprotein cells. A small quantity of ligand can activate ER pathway effectively. ER depend on estrogen effect to induce gene transcription and promote proliferation of tumor cells.
PR is end products, which can be affected by estrogen. Estrogen promotes the synthesis of PR. ER expression levels are important factors which affect PR expression, the higher the positive degree of ER, the more PR expression, activity and the pathway of ER is a key factor for PR expression.
C-erbB-2 is a proto-oncogene, which plays a decisive role in growth factor signaling pathways and controls normal cell growth and differentiation. Growth factors and C-erbB-2 receptor on the cell surface can activate intracellular tyrosine kinase, and then cause phosphorylation of tyrosine itself, which may keep triggering a cascade of chain reactions. The signals through the cell membrane and the stromal cells spreads into the nucleus, which activate C-erbB-2 gene, accelerate mitosis, regulate cell growth and promote the proliferation and differentiation of malignant tumor, its overexpression prompts C-erbB-2 gene amplification infinitely, and then promotes C-erbB-2 gene transcription, increases replication, and keeps enhancing C-erbB-2mRNA translation level and C-erbB-2 receptors synthesis and overexpression, this can induce signaling pathways activated through ligand binding, keep triggering the growth and differentiation of tumor cell infinitely. C-erbB-2 is also a drug-resisted gene. The higher the positive rate of C-erbB-2, the stronger the cancer cells resists. Because genotyping of breast cancer may affect the biological behavior of tumors and the sensitivity of chemotherapy. Therefore, depending on test of tumor susceptibility, establishing relationship of ER, PR, C-erbB-2 and the anti-tumor drugs, and then guided the selection of clinical personalized medicine. Chemotherapy will be more focused treatment.
Materials and Methods
1 Specimen
Breast surgical treatment of 69 hospitalized patients were collected from July 2008 to December 2009 at the Second Affiliated Hospital of Zhengzhou University. Intraoperative frozen section and routine pathological examination confirmed breast cancer after radical mastectomy or breast conserving surgery. We will detect ER, PR, C-erbB-2 simultaneously. Tumor specimens were immediately sent to the laboratory for the following treatment to avoid specimens contamination,①We use culture medium of RMPI-1640 to wash specimens three times in 15ml culture tubes;②We add with amount of RMPI-1640 involved 100U/ml penicillin and streptomycin to immerse specimens at twenty minutes, after completion of the deal, under the principle in sterile, clipping specimens to process the next step.
2 Research methods
The specimens were made into single cell suspension, then we examine cells degrees and counting, adjust the cell concentration, establish the experimental group, control group and cell control group. Various drugs are diluted to experimental liquids. We may add the liquids to 96 holes training board to cultivate specimens four days later, and add again 0.5% MTT cultivating and dissolved. We axamine absorbency in the microplate reader to calculate inhibiting rate of tumor cells in every hole.
3 Evaluation Criteria
5PPC solution serves as the concentration of drug sensitivity. Criteria of evaluation are that high sensitivity of tumor inhibiting rate is above 50%, sensitivity of tumor inhibiting rate is between 30%-50%, inhibiting rate of tumor cells of resistance is below 30%.
4 Statistic analysis
In this study, All the data were expressed by (x±s). The statistical software SSPS17.0 for windows was exploited to analyze data. Which was processed the test of homogeneity of variance and normality, Deviation and difference were compared using the one way ANOVA and LSD test between each group, The different significance is judged by P<0.05.
Results
The four specimens of ER(+), PR(+), C-erbB-2(-), ER(+), PR(+), C-erbB-2(+), ER(-), PR(-), C-erbB-2(-) and ER(-), PR(-), C-erbB-2(+) do not reflect the significant difference in fluorouracil(P>0.05). The ER(+), PR(+), C-erbB-2(-) have an advantage over ER(+), PR(+), C-erbB-2(+), ER(-), PR(-), C-erbB-2(-) and ER(-), PR(-), C-erbB-2(+) in methotrexate(P<0.05). The ER(+), PR(+), C-erbB-2(-) have an advantage over ER(-), PR(-), C-erbB-2(-) and ER(-), PR(-), C-erbB-2(+) in adriamycin(P<0.05); The ER(+), PR(+), C-erbB-2(-) have an advantage over ER(-), PR(-), C-erbB-2(+) in epirubicin (P<0.05). The ER(+), PR(+), C-erbB-2(-) have an advantage over ER(+), PR(+), C-erbB-2(+), ER(-), PR(-), C-erbB-2(-) and ER(-), PR(-), C-erbB-2(+) in paclitaxel(P<0.05).
Conclusions
1. The experiments shows that genotypes are correlate with sensitivity of chemotherapy in breast cancer. ER(+), PR(+), C-erbB-2(-), ER(+), PR(+), C-erbB-2(+) and ER(-), PR(-), C-erbB-2(-) three types of cells have the same orders in various inhibiting rates in anticancer drugs:PTX> EPI> ADM> 5-FU> MTX. ER(-), PR(-), C-erbB-2(+) cells has a different inhibiting effect on a variety of anticancer, its sequence follows as:PTX> ADM> EPI> 5-FU> MTX.
2. Different genotypes of breast cancer have different inhibiting rates to the same chemotherapeutic drug, which suggests that they have different chemotherapeutic benefit. Paclitaxel, doxorubicin, epirubicin, fluorouracil and methotrexate have the highest inhibiting effect in the ER(+), PR (+), C-erbB-2(-). All five drugs have the lowest inhibiting effect in the ER(-), PR(-), C-erbB-2(-). Based on the different genotypes, we choose sensitive drugs so as to obtain maximum benefit of treatment and achieve individualized treatment for breast cancer.
引文
[1]Berry DA, Cirrincione C, Henderson IC, et al. Estrogen receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.JAMA,2006,295 (14): 1658-1667.
[2]马永录,李红生,张广林.乳腺癌新辅助化疗与雌激素受体、孕激素受体的相关性研究[J].卫生职业教育,2008,26(19)：150-151.
[3]Prati R, Apple SK, He J, et al. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer [J]. Breast J,2005,11(6):433-439.
[4]Dimas C, Frangos PM, Kouskouni E, et al. Immunohistochemical study of p185 HER2 and DF3 in primary breast cancer and correlation with CA-15-3 serum tumor marker[J]. Int J Gynecol Cancer,2002,12(1):74-79.
[5]Shimada M, Imura J, Kozaki T, et al. Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast Cancer progression using fluorescence in situ hybridization[J]. Oncol Rep,2005,13(4):633-641.
[6]Al-Ahwal MS. HER-2 positivity and correlations with other histopathologic features in breast cancer patients-hospital based study[J]. J Pak Med Assoc,2006,56(2):65-68.
[7]Sahin AA. Biologic and clinical significance of HER-2/neu (C-erbB-2) in breast cancer[J]. Adv anat Pathol,2000,7(3):158-166.
[8]Stal O, Sullivan S, Wingren S, et al. C-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer,1995,31A:2185-2190.
[9]Miles DW, Harris WH, Gillett CE, et al. Effect of C-erbB-2 and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/ methotrexate/fluorouracil. Int J Cancer,1999.84(4):354-359.
[10]Yang W, Klos KS, Zhou X, et al. ErbB2 overexpression in human breast carcinoma is correlated with p21 Cipl up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophosphamide methotrexate, and 5-Fluorouracil is assoiated with Erb2 overexpression and with p2lCipl overexpression. Cancer.2003.98(6):1123-1130.
[11]Ueno NT, Yu D, Hung MC. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel(Taxol) by adenovirus type 5 E1A. Oncogene,1997,15(8): 953-960.
[12]Konecny GE, Thomssen C, Luck HJ, et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst.2004,96(15): 1141-1151.
[13]Gregory RK, Powles TJ, Salter J, et al. Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy[J]. Breast Cancer Res Treat,2000,59(2): 171-175.
[14]Moliterni A, Me'nard S, Valagussa P, et al. HER2 Overexpression and Doxorubicinin Adjuvant Chemotherapy for Resectable Breast Cancer. (2003) J Clin Oncol,21(3): 458-462.
[15]Buchholz TA, Stivers DN, Houston, et al. Global Gene Expression Changes During Neoadjuvant Chemotherapy for Human Breast Cancer. (2002)The Cancer Journal,8(6): 461-468.
[16]Ayers M, Symmans WF, Stec J, et al. Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer. (2004) J Clin Oncol,22(12): 2284-2293.
[17]Carey LA, Perou CM, Livasy C, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA,2006,295(21):2492-2502
[18]韩锐,主编.肿瘤化学预防及药物治疗[M].第1版.北京：北京医科大学中国协和医科大学联合出版社出版,1991,418-421.
[19]宋海平,黄韬,田元.乳腺癌细胞的原代分离培养及药物敏感性试验研究[J].中华普通外科杂志,2005,20(8)：525-526.
[20]Sieuwerts AM, Klijin JG, Peters HA, et al. The MTT tetrazolium salt assay scrutinized[J]. Eur J Clin Chem Clin Biochem,1995,33(11):813-823.
[21]Fricker SP, Buckley RG. Comparison of two colorimetric assays as cytotoxicity endpoints for an in vitro screen for antitumor agents[J]. Anticancer Res,1996,16(6B):3755-3760.
[22]Chen CF, Hwang JM, Wu CH, et al. Evaluation of a rapid tetrazolium-based colorimetric assays for selecting anticancer drugs[J]. Chin Med J(Taipei),1990,46(1):7-16.
[23]Plumb JA, Milroy R, Kaye SB, et al. Effects of the pH dependence of MTT bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay[J]. Cancer Res,1989,49(16):4435-4440.
[24]Rouzier R, et al. Clin Cancer Res,2005,11(16):5678-5685.
[25]Calza S, et al. Breast Cancer Res,2006,8(4):R34.
[26]Horwitz KB, Koseki Y, McGuire WL, Estrogen control of progesterone receptor in human breast cancer:role of estradiol and antiestrogen. Endocrinology,1978,103(5):1742-1751.
[27]Horwitz KB, McGuire WL. Estrogen control of progesterone receptor in human breast cancer.Correlation with nuclear processing of estrogen receptor. J Biol Chem,1978,253(7): 2223-2228.
[28]Anderson WT, Chatterjee N, Ershler WB, et al. Estrogen receptor breast cancer phenotypes in the surveillance,epidemiology, and end results database. Breast Cancer Res Treat,2002. 76(1):27-36.
[29]Huang HJ, Neven P, Drijkoningen M, et al. Association between tumor characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast Cancer. J Clin Pathol,2005,58(6):611-616.
[30]Arpino G, Weiss H, Lee AV, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer:association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst,2005,97(17):1254-1261.
[31]何洛文,赵敏,刘美生,等.乳腺癌C-erbB-2基因扩增的初步研究[J].中华肿瘤杂志,1992,14(3)：171-174.
[32]Borg A, Tandon AK, Sigurdsson H, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer [J]. Cancer Res,1990,50(14):4332-4337.
[33]Kepple J, Henry-Tillman RS, Klimberg VS, et al. The receptor expression pattern in ductal carcinoma in situ predicts recurrence[J]. AmJ Surg,2006,192(1):68-71.
[34]Robertson KW, ReevesJR, Smith G, et al. Quantitative estimation of epidermal growth factor receptor and C-erbB-2 in human breast cancer[J]. Cancer Res,1996,56(16): 3823-3830.
[35]曲建军,石毅然.MUC1与HER2基因在乳腺癌中的研究进展[J].中国肿瘤临床,2005,18(32)：1073-1075.
[36]Petit T, Borel C, Ghnassia JP, et al. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res, 2001,7(6):1577-1581.
[37]Muss HB, Thor AD, Berry DA, et al. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med,1994,330(18): 1260-1266.
[38]Ueno NT, Yu D, Hung MC. Chemosensitization of HER-2/neu overexpressing human breast cancer cells to paclitaxel(Taxo1) by adenovirus type 5EIA. Oncogene,1997,15 (8): 953-960.
[39]Ciardiello F, Caputo R, Pomatico G, et al. Resistance to taxanes is induced by C-erbB-2 overexpressing in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A. Int J Cancer. 2000,85 (5):710-715.
[40]Konecny GE, Thomssen C, Luck HJ, et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst.2004,96(15): 1141-1151.
[41]傅喆暾,袁杰,黄雄伟,等.植物抗癌药紫杉醇的研究进展[J].现代中药研究与实践,2006,20(3)：58-61.
[1]Kuiper GG, Enmark E, Pelto Huikko M, et al. Cloning of a novel receptor expressed in rat prostate and ovary[J]. Proc Natl Acad Sci USA.1996,93(12):5925-5930.
[2]Paech K, Webb P, Kuiper G, et al. Differential ligand activation of estrogen receptors ER alpha and ER beta at AP1 sites[J]. Science,1997,277(5331):1508-1510.
[3]Roger P, Sahla ME, Makela S, et al. Decreased expression of estrogen receptor β protein in proliferative preinvasive mammary tumors[J]. Cancer Res,2001,61(6):2537-2541.
[4]Skliris GP, Munot K, Bell SM. et al. Reduced expression of Estrogen receptor β in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model[J]. J Pathol 2003,201(2):213-220.
[5]Shaaban AM, Nem PA, Davies MP, et al. Declining estrogen receptor-β expression defines malignant progression of human breast neoplasia[J]. Am J surg Pathol,2003, 27(12):1502-1512.
[6]Omoto Y, Kobayashi S, Inoue S, et al. Evaluation of estrogen receptor β wild-type and variant protein expression,and relationship with clinicopathological factors in breast cancers [J]. Eur J Cancer,2002,38(3):380-386
[7]Murphy L, Leygue E, Niu Y, et al. Relationship of coregulator and estrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer[J]. British Journal of Cancer,2002.87(12):1411-1416.
[8]Mac Gregor Schafer J, Liu H, Levenson AS, et al. Estrogen receptor alpha mediated induction of the transforming growth factor alpha gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cells[J]. J Steroid Biochem Mol Biol, 2001,78(1):41-50.
[9]Berry DA, Cirrincione C, Henderson IC, et al. Estrogen receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer[J]. JAMA,2006, 295(14):1658-1667.
[10]马永录,李红生,张广林,等.乳腺癌新辅助化疗与雌激素受体、孕激素受体的相关性研究[J].卫生职业教育,2008,26(19),150-151.
[11]Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer.College of American Pathologists Consensus Statement 1999[J]. Arch Pathol Lab Med,2000,124(7): 966-978
[12]Kobayashi S, Iwase H, Ito Y, et al. Clinical significance of bcl-2 gene expression in human breast cancer tissues[J]. Breast Cancer Res Treat,1997,42(2):173-181
[13]Toi M, Inada K, Suzaki H, et al. Tumor angiogenesis in breast cancer:its importance as a prognostic indicator and association with vascular endothelial growth factor expression[J]. Breast Cancer Res Treat,1995,36(2):193-204.
[14]Laughner E, Taghavi P, Chiles K, et al. HER-2(neu)signaling increases the rate of hypoxia-inducible factor lalpha (HIF-lalpha) synthesis:novel mechanism for HIF-1-mediated vscular endothelial growth factor expression[J]. Mol Cel Biol,2001, 21(12):3995-4004.
[15]Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Relation of hypoxia inducible factor 1 and 2(in operable non-small cell lung cancer to angiogenic/molecular profile of tumors and survival [J]. Br J Cancer,2001,85(6):881-890.
[16]Alicia ZS, Blanca OS, Mariana GH, et al. Rapid production of candida albicans chlamydospores in liquid media under various incubation conditions[J]. Nippon Ishinkin Gakkai Zasshi,2006,47(3):231-234
[17]Ellis MJ, Coop A, Singh B, et al. Letrozole inhibits tumor proliferation more efectively thantamoxifen independent of HER 1/2 expression status[J]. Cancer Res,2003,63(19): 6523-6531.
[18]Gregory RK, Powles TJ, Salter J, et al. Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy [J]. Breast Cancer Res Treat,2000,59(2): 171-175.
[19]Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature, 2000,406(6797):747-752.
[20]Yamamoto Y, Ibusuki M, Kawasoe T. Basal cell-like signature is an independent prognostic factor in triple-negative breast cancer[J]. J Clin Oncol,2008,26(suppl):22184.
[21]Tohfe MA, Chamsedine N, Ghandour F. Triple-negative phenotype of breast cancer and its association with poor prognostic factors [J]. J Clin Oncol,2008,26(suppl):22134.
[22]Haffty BG, Yang Q, Reiss M. et al. Locoregional and distant metastasis in conservatively managed triple negative early-stage breast cancer[J]. J Clin Oncol,2006,24(3):5652-5655.
[23]Khan AM, Sabnani I, Tsang P. Triple-negative early-stage breast cancer in African American women:A fuel to the fire[J]. J Clin Oncol,2008,26(suppl):1039.
[24]Choi MY, Lee KE, Chang HJ. Prognostic significance of triple-negative phenotype in breast cancer[J]. J Clin Oncol,2008,26(suppl):11587.
[25]Dent R, Trudeau M, Pritchard KI, et al. TN Breast Cancer:Clinical Features and Patterns of Recurrence[J]. Clin Cancer Res,2007,13(2):4429-4434.
[26]Palmieri D. Brain metastases of breast cancer[J]. Breast Dis,2007,26(3):139-147.
[27]Carey LA, Dees EC, Sawyer L, et al. The Triple Negative Paradox:Primary Tumor Chemosensitivity of Breast Cancer Subtypes. Clin Cancer Res,2007,13(8):2329.
[28]Rodenhuis S, Bontenbal M, van Hoesel QG, et al. Efficacy of high-dose alkylating chemotherapy in HER-2/neu-negative breast cancer. Ann Oncol,2006,17(4):588-596.
[29]Lippman ME, Allegra JC, ThompsonEB, et al. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med, 1978,298(22):1223.
[30]Berry DA, Cirrincione C, Henderson IC, et al. Effects of improvements in chemotherapy on disease-free and overall survival of estrogen-receptor negative, node-positive breast cancer:20-year experience of the CALGB and US Breast Intergroup.27th Annual San Antonio Breast Cancer Symposium,2004.
[31]Brenton JD, Carey LA, Ahmed AA, et al. Molecular classification and molecular forecasting of breast cancer:Ready for clinical application? J Clin Oncol,2005,23(29): 7350-7360.
[32]Rodenhuis S, Bontenbal M, van Hoesel QG, et al. Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer.Ann Oncol,2006,17(4):588.
[33]Nitz UA, Gluz O, Herr A, et al. Retrospective analysis of WSG AM01 tandem high dose chemotherapy trial in high risk primary breast cancer:A hypothesis generating study.Proc Am Soc Clin Oncol,2006,24:665(Abstr).
[34]Koizumi S, Curt GA, Fine RL, et al. Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow. Journ Clin Invest,1985,75(3): 1008-1014.
[35]Saxena M, Henderson GB. Identification of efflux systems for large anions and anionic conjugates as the mediators of methotrexate efflux in L1210 cells[J]. Biochem Pharmacol, 1996,51(7):974-982.
[36]Dicker AP, Waltham MC, Volkenandt M, et al. Methotrexate resistance in an in vivo mouse tumor due to a non-active-site dihydrofolate reductase mutation[J]. Proc Natt Acad Sci USA,1993,90(24):11797-11801.
[37]Beijersbergen JR, Bernards R. Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins[J]. Biochem Biophys Acta,1996,1287(2-3):103-120.
[38]Jansen G, Pieters R. The role of impaired transport in(pre) clinical resistance to methotrexate:insights on new antifolates [J]. Drug Res Updates,1998,1(3):211-218.
[39]Moscow JA. Methotrexate transport and resistance[J]. Leuk Lymphoma,1998,30(3-4): 215-224.
[40]Xiao H, Verdier P, Fernandez N, et al. insights into the mechanism of microtubule stabilization by taxol[J]. Proc Natl Acad Sci.2006,103(27):10166-10173.
[41]Mielke. Individualized pharmacotherapy with paclitaxel [J]. Curr Opin Oncol,2007,19(6): 586-589.
[42]Swanton C, Marani M, Pardo O, et al. Regulators of mitotic arrest and ceramide metabolism am determinants of sensitivity to paclitaxel and other chemotherapeutic drugs[J]. Cancer Cell,2007,11(6):498-512.
[43]Wiesen KM, Xia S, Yang CP, et al. Wild-type class I beta-tubulin sensitizes Taxol-resistant breast adenocarcinoma cells harboring a beta-tubulin mutation[J]. Cancer Lett,2007,18,257(2):227-235.
[44]Wang Y, O Brate A, Zhou W, et al. Resistance to microtubule-stabilizing drugs involves two events:beta-tubulin mutation in one allele followed by loss of the second allele[J]. Cell Cycle,2005,4(12):1847-1853.
[45]Kavallaris M, Kuo DY, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest,1997, 100(5):1282-1293.
[46]Verdier Pinard P, Wang F, Martello L, et al. Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusingand mass spectrometry. Biochemistry,2003,42(18):5349-5357.
[47]Hari M, Yang H, Zeng C, et al. Expression of class Ⅲ beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskeleton,2003,56(1):45-56.
[48]Kamath K, Wilson L, Cabral F, et al. Beta Ⅲ-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability:J Biol Chem,2005, 280(13):12902-12907.
[49]Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase[J]. Clin Cancer Res,2000,6(4): 1322-1327.
[50]岳瑶,5-氟尿嘧啶的耐药与逆转研究进展[J].临床肿瘤学杂志,2003,8(5)：1387-1388.
[51]Kornmann M, Schwabe W, Sander S, et al. thymidylate synthase and dihydropyrimidine dehydrogenase mrna expression levels:predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil[J]. Clin Cancer Res,2003,9(9):4116-4224.
[52]Kurebayashi J, yamamoto Y, Udagawa K, et al. establishment of enzyme-linked immunosorbent assays for thymidylate synthase and dihydropyrimidine dehydrogenase in cancer tissues. Oncol Rep,2004,11(5):973-979.
[53]Li HX, Zh S, Zhang YH, et al. Expressions of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase in breast cancer and their correlations with prognosis. Zhonghua Zhong Liu Za Zhi,2004,26(11):669-672.
[54]sasaki H, Fukai I, Kiriyama M, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in thymoma [J]. Surg Today.2003,33(2):183-188.
[55]Etienne MC, cheradame S, Fischel JL, et al. Response to flourouracil therapy in cancer patients:the role of tumoral dihydropyrimidine dehydrpgenase activity[J]. J Clin Oncol, 1995,13(7):1663-1670.
[56]Terashima M, Irinoda T, Fujiwara H, et al. Roles of thymidylate synthase and dihydropyrimidine dehydrpgenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer[J]. Anticancer Res,2002,22(2A):761-768.
[57]Kralovanszky J, Koves I, Orosz Z, et al. Prognostic significance of the thymidylate biosynthetic enzymes in human colorectal tumors[J]. Oncology.2002,62(2):167-174.
[58]Matsushita S, Nitanda T, Furukawa T, et al. The effect of a thimidine phosphorylase inhibition angiogenesis and apoptosis in tumors[J]. Cancer Res,1999,59(9):1911-1916.
[59]Fukushima M, Okabe H, Takechi T, et al. Induction of thimidine phosphorylase by interferon and taxanes occurs only in human cancers cells with low thimidine phosphorylase activity[J]. Cancer Lett,2002,187(1-2):103-110.
[60]Goto H, kohno K, Sone S, et al. Interferon gamma-dependent induction of thimidine phosphorylase/platelet-derived endothelial cell growth factor through gamma-activated sequence-like element in human macrophages[J]. Cancer Res,2001,61(2):469-473.
[61]Patterson AV, Zhang H, Moghaddam A, et al. Increased sensitivity to the prodrug 5-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thimidine phosphorylase[J]. Br J Cancer,1995,72(3):669-675.
[62]Eda H, Fujimoto K, Watanabe S, et al. Cytokines induce thimidine phosphorylase expression in tumor cells and make them more susceptible to 5-deoxy-5-fluorouridine[J]. Cancer Chemother Phamacol,1993,32(5):333-338.
[63]Ambrosone CB, Sweeney C, Coles BF, et al. Polymorphism in glutathione S-transferases (GSTM1 and GSTM2) and survival after treatment for breast cancer[J]. Cancer Res,2001, 61(19):7130-7135.
[64]Howells RE, Dhar KK, Hoban PR, et al. Association between glutathione S transferase GSTP1 genotypes, GSTP1 overexpression and outcome in epithelial ovarian cancer[J]. Int J Gynecol Cancer,2004,14(2):242-250.
[65]Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance[J]. Oncogene,2003,22(47):7369-7375.
[66]Kruh GD, Belinsky MG. The MRP family of drug efflux pumps [J]. Oncogene,2003, 22(47):7537-7552.
[67]Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP(ABCG2)[J]. Oncogene,2003,22 (47):7340-7358.
[68]Sun J, He ZG, cheng G, et al. Multidrug resistence p-glycoprotein.crucial significance in drug disposition and interaction[J]. Med Sci Monit,2004,10(1):5.
[69]Ambudkar SV, Kimchi-sarfaty C, Sauna ZE, et al. P-glycoprotein from genomics to mechanism[J]. Oncogene,2003,22(47):7468.
[70]Pastan I, Gottesman M. Multiple-drug resistance in human cancer[J]. N Engl J Med,1987, 316(22):1388-1393.
[71]Lautier D, Canitrot Y, Deeley RG, et al. Multidrug resistance mediated by the multidrug resistance protein(MRP) gene[J]. Biochem Pharmacol.1996,52(7):967-977.
[72]Sharp SY, Smith V, Hobbs S, et al. Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines[J]. Br J Cancer,1998,78(2):175-180.
[73]Kool MDE, Hass M, Scheffer GI, et al. Analysis of expression of EMOAT(MRP2)、 MRP3、MRP4 and MRP5, homologues of the multidrug resistance-associated protein gene(MRP1), in human cancer cell lines[J]. Cancer Res,1997,57(8):3537-3547.
[74]Scheper RJ, Broxterman HJ, Scheffer GL, et al. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-meidiated multidrug resistance. Cancer Res,1993, 53(7):1475-1479.
[75]徐兵河,蒽环类耐药性乳腺癌的治疗策略[J].中华肿瘤杂志,2007,29(4)：241-244.
[76]Xu BH, Singh SV. Efect of buthionine sulfoximine and ethacrynic acid on cytotoxic activity of mitomycin C analogues BMY 25282 and BMY 25067. Cancer Res,1992, 52 (23):6666-6670.
[77]Xu BH, Gupta V, Singh SV. Characterization of a human bladder cancer cell line selected for resistance to mitomycin C. Int J Cancer,1994,58 (5):686-692.
[78]Airoldi M, Cattel L, Pedani F, et al. Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycine resistant/relapsed metastatic breast cancer. Acta Oncol,2003,42 (3):186-194.
[79]Maiche AG, Jekumen AP, Kaleva-Kerola J, et al. High response rate with a lower dose of paclitaxel in combination with cispahin in heavily pretreated patients with advanced breast carcinoma. Cancer,2000,88(8):1863-1868.
[80]O'shaughnessy J, Miles D, Vakelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer:phaseⅢ trial results. J Clin Oncol,2002,20 (12):2812-2823.
[81]Blum JL, Dieras V, Lo Russo PM, et al. Multicenter phaseⅡ study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer,2001,92(7):1759-1768.
1刘予生,陈建中.三苯氧胺与乳癖散结在乳腺增生中的临床应用[J].中国实用医刊,2010,37(8)：68～69.
2刘予生,刘志强,徐霓.计算机辅助设计系统在乳房再造中的实用性分析[J].河南医学研究,2009,18(4)：333～334.
[2]马永录,李红生,张广林.乳腺癌新辅助化疗与雌激素受体、孕激素受体的相关性研究[J].卫生职业教育,2008,26(19)：150-151.
[3]Prati R, Apple SK, He J, et al. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer [J]. Breast J,2005,11(6):433-439.
[4]Dimas C, Frangos PM, Kouskouni E, et al. Immunohistochemical study of p185 HER2 and DF3 in primary breast cancer and correlation with CA-15-3 serum tumor marker[J]. Int J Gynecol Cancer,2002,12(1):74-79.
[5]Shimada M, Imura J, Kozaki T, et al. Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast Cancer progression using fluorescence in situ hybridization[J]. Oncol Rep,2005,13(4):633-641.
[6]Al-Ahwal MS. HER-2 positivity and correlations with other histopathologic features in breast cancer patients-hospital based study[J]. J Pak Med Assoc,2006,56(2):65-68.
[7]Sahin AA. Biologic and clinical significance of HER-2/neu (C-erbB-2) in breast cancer[J]. Adv anat Pathol,2000,7(3):158-166.
[8]Stal O, Sullivan S, Wingren S, et al. C-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer,1995,31A:2185-2190.
[9]Miles DW, Harris WH, Gillett CE, et al. Effect of C-erbB-2 and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/ methotrexate/fluorouracil. Int J Cancer,1999.84(4):354-359.
[10]Yang W, Klos KS, Zhou X, et al. ErbB2 overexpression in human breast carcinoma is correlated with p21 Cipl up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophosphamide methotrexate, and 5-Fluorouracil is assoiated with Erb2 overexpression and with p2lCipl overexpression. Cancer.2003.98(6):1123-1130.
[11]Ueno NT, Yu D, Hung MC. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel(Taxol) by adenovirus type 5 E1A. Oncogene,1997,15(8): 953-960.
[12]Konecny GE, Thomssen C, Luck HJ, et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst.2004,96(15): 1141-1151.
[13]Gregory RK, Powles TJ, Salter J, et al. Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy[J]. Breast Cancer Res Treat,2000,59(2): 171-175.
[14]Moliterni A, Me'nard S, Valagussa P, et al. HER2 Overexpression and Doxorubicinin Adjuvant Chemotherapy for Resectable Breast Cancer. (2003) J Clin Oncol,21(3): 458-462.
[15]Buchholz TA, Stivers DN, Houston, et al. Global Gene Expression Changes During Neoadjuvant Chemotherapy for Human Breast Cancer. (2002)The Cancer Journal,8(6): 461-468.
[16]Ayers M, Symmans WF, Stec J, et al. Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer. (2004) J Clin Oncol,22(12): 2284-2293.
[17]Carey LA, Perou CM, Livasy C, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA,2006,295(21):2492-2502
[18]韩锐,主编.肿瘤化学预防及药物治疗[M].第1版.北京：北京医科大学中国协和医科大学联合出版社出版,1991,418-421.
[19]宋海平,黄韬,田元.乳腺癌细胞的原代分离培养及药物敏感性试验研究[J].中华普通外科杂志,2005,20(8)：525-526.
[20]Sieuwerts AM, Klijin JG, Peters HA, et al. The MTT tetrazolium salt assay scrutinized[J]. Eur J Clin Chem Clin Biochem,1995,33(11):813-823.
[21]Fricker SP, Buckley RG. Comparison of two colorimetric assays as cytotoxicity endpoints for an in vitro screen for antitumor agents[J]. Anticancer Res,1996,16(6B):3755-3760.
[22]Chen CF, Hwang JM, Wu CH, et al. Evaluation of a rapid tetrazolium-based colorimetric assays for selecting anticancer drugs[J]. Chin Med J(Taipei),1990,46(1):7-16.
[23]Plumb JA, Milroy R, Kaye SB, et al. Effects of the pH dependence of MTT bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay[J]. Cancer Res,1989,49(16):4435-4440.
[24]Rouzier R, et al. Clin Cancer Res,2005,11(16):5678-5685.
[25]Calza S, et al. Breast Cancer Res,2006,8(4):R34.
[26]Horwitz KB, Koseki Y, McGuire WL, Estrogen control of progesterone receptor in human breast cancer:role of estradiol and antiestrogen. Endocrinology,1978,103(5):1742-1751.
[27]Horwitz KB, McGuire WL. Estrogen control of progesterone receptor in human breast cancer.Correlation with nuclear processing of estrogen receptor. J Biol Chem,1978,253(7): 2223-2228.
[28]Anderson WT, Chatterjee N, Ershler WB, et al. Estrogen receptor breast cancer phenotypes in the surveillance,epidemiology, and end results database. Breast Cancer Res Treat,2002. 76(1):27-36.
[29]Huang HJ, Neven P, Drijkoningen M, et al. Association between tumor characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast Cancer. J Clin Pathol,2005,58(6):611-616.
[30]Arpino G, Weiss H, Lee AV, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer:association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst,2005,97(17):1254-1261.
[31]何洛文,赵敏,刘美生,等.乳腺癌C-erbB-2基因扩增的初步研究[J].中华肿瘤杂志,1992,14(3)：171-174.
[32]Borg A, Tandon AK, Sigurdsson H, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer [J]. Cancer Res,1990,50(14):4332-4337.
[33]Kepple J, Henry-Tillman RS, Klimberg VS, et al. The receptor expression pattern in ductal carcinoma in situ predicts recurrence[J]. AmJ Surg,2006,192(1):68-71.
[34]Robertson KW, ReevesJR, Smith G, et al. Quantitative estimation of epidermal growth factor receptor and C-erbB-2 in human breast cancer[J]. Cancer Res,1996,56(16): 3823-3830.
[35]曲建军,石毅然.MUC1与HER2基因在乳腺癌中的研究进展[J].中国肿瘤临床,2005,18(32)：1073-1075.
[36]Petit T, Borel C, Ghnassia JP, et al. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res, 2001,7(6):1577-1581.
[37]Muss HB, Thor AD, Berry DA, et al. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med,1994,330(18): 1260-1266.
[38]Ueno NT, Yu D, Hung MC. Chemosensitization of HER-2/neu overexpressing human breast cancer cells to paclitaxel(Taxo1) by adenovirus type 5EIA. Oncogene,1997,15 (8): 953-960.
[39]Ciardiello F, Caputo R, Pomatico G, et al. Resistance to taxanes is induced by C-erbB-2 overexpressing in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A. Int J Cancer. 2000,85 (5):710-715.
[40]Konecny GE, Thomssen C, Luck HJ, et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst.2004,96(15): 1141-1151.
[41]傅喆暾,袁杰,黄雄伟,等.植物抗癌药紫杉醇的研究进展[J].现代中药研究与实践,2006,20(3)：58-61.
[1]Kuiper GG, Enmark E, Pelto Huikko M, et al. Cloning of a novel receptor expressed in rat prostate and ovary[J]. Proc Natl Acad Sci USA.1996,93(12):5925-5930.
[2]Paech K, Webb P, Kuiper G, et al. Differential ligand activation of estrogen receptors ER alpha and ER beta at AP1 sites[J]. Science,1997,277(5331):1508-1510.
[3]Roger P, Sahla ME, Makela S, et al. Decreased expression of estrogen receptor β protein in proliferative preinvasive mammary tumors[J]. Cancer Res,2001,61(6):2537-2541.
[4]Skliris GP, Munot K, Bell SM. et al. Reduced expression of Estrogen receptor β in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model[J]. J Pathol 2003,201(2):213-220.
[5]Shaaban AM, Nem PA, Davies MP, et al. Declining estrogen receptor-β expression defines malignant progression of human breast neoplasia[J]. Am J surg Pathol,2003, 27(12):1502-1512.
[6]Omoto Y, Kobayashi S, Inoue S, et al. Evaluation of estrogen receptor β wild-type and variant protein expression,and relationship with clinicopathological factors in breast cancers [J]. Eur J Cancer,2002,38(3):380-386
[7]Murphy L, Leygue E, Niu Y, et al. Relationship of coregulator and estrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer[J]. British Journal of Cancer,2002.87(12):1411-1416.
[8]Mac Gregor Schafer J, Liu H, Levenson AS, et al. Estrogen receptor alpha mediated induction of the transforming growth factor alpha gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cells[J]. J Steroid Biochem Mol Biol, 2001,78(1):41-50.
[9]Berry DA, Cirrincione C, Henderson IC, et al. Estrogen receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer[J]. JAMA,2006, 295(14):1658-1667.
[10]马永录,李红生,张广林,等.乳腺癌新辅助化疗与雌激素受体、孕激素受体的相关性研究[J].卫生职业教育,2008,26(19),150-151.
[11]Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer.College of American Pathologists Consensus Statement 1999[J]. Arch Pathol Lab Med,2000,124(7): 966-978
[12]Kobayashi S, Iwase H, Ito Y, et al. Clinical significance of bcl-2 gene expression in human breast cancer tissues[J]. Breast Cancer Res Treat,1997,42(2):173-181
[13]Toi M, Inada K, Suzaki H, et al. Tumor angiogenesis in breast cancer:its importance as a prognostic indicator and association with vascular endothelial growth factor expression[J]. Breast Cancer Res Treat,1995,36(2):193-204.
[14]Laughner E, Taghavi P, Chiles K, et al. HER-2(neu)signaling increases the rate of hypoxia-inducible factor lalpha (HIF-lalpha) synthesis:novel mechanism for HIF-1-mediated vscular endothelial growth factor expression[J]. Mol Cel Biol,2001, 21(12):3995-4004.
[15]Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Relation of hypoxia inducible factor 1 and 2(in operable non-small cell lung cancer to angiogenic/molecular profile of tumors and survival [J]. Br J Cancer,2001,85(6):881-890.
[16]Alicia ZS, Blanca OS, Mariana GH, et al. Rapid production of candida albicans chlamydospores in liquid media under various incubation conditions[J]. Nippon Ishinkin Gakkai Zasshi,2006,47(3):231-234
[17]Ellis MJ, Coop A, Singh B, et al. Letrozole inhibits tumor proliferation more efectively thantamoxifen independent of HER 1/2 expression status[J]. Cancer Res,2003,63(19): 6523-6531.
[18]Gregory RK, Powles TJ, Salter J, et al. Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy [J]. Breast Cancer Res Treat,2000,59(2): 171-175.
[19]Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature, 2000,406(6797):747-752.
[20]Yamamoto Y, Ibusuki M, Kawasoe T. Basal cell-like signature is an independent prognostic factor in triple-negative breast cancer[J]. J Clin Oncol,2008,26(suppl):22184.
[21]Tohfe MA, Chamsedine N, Ghandour F. Triple-negative phenotype of breast cancer and its association with poor prognostic factors [J]. J Clin Oncol,2008,26(suppl):22134.
[22]Haffty BG, Yang Q, Reiss M. et al. Locoregional and distant metastasis in conservatively managed triple negative early-stage breast cancer[J]. J Clin Oncol,2006,24(3):5652-5655.
[23]Khan AM, Sabnani I, Tsang P. Triple-negative early-stage breast cancer in African American women:A fuel to the fire[J]. J Clin Oncol,2008,26(suppl):1039.
[24]Choi MY, Lee KE, Chang HJ. Prognostic significance of triple-negative phenotype in breast cancer[J]. J Clin Oncol,2008,26(suppl):11587.
[25]Dent R, Trudeau M, Pritchard KI, et al. TN Breast Cancer:Clinical Features and Patterns of Recurrence[J]. Clin Cancer Res,2007,13(2):4429-4434.
[26]Palmieri D. Brain metastases of breast cancer[J]. Breast Dis,2007,26(3):139-147.
[27]Carey LA, Dees EC, Sawyer L, et al. The Triple Negative Paradox:Primary Tumor Chemosensitivity of Breast Cancer Subtypes. Clin Cancer Res,2007,13(8):2329.
[28]Rodenhuis S, Bontenbal M, van Hoesel QG, et al. Efficacy of high-dose alkylating chemotherapy in HER-2/neu-negative breast cancer. Ann Oncol,2006,17(4):588-596.
[29]Lippman ME, Allegra JC, ThompsonEB, et al. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med, 1978,298(22):1223.
[30]Berry DA, Cirrincione C, Henderson IC, et al. Effects of improvements in chemotherapy on disease-free and overall survival of estrogen-receptor negative, node-positive breast cancer:20-year experience of the CALGB and US Breast Intergroup.27th Annual San Antonio Breast Cancer Symposium,2004.
[31]Brenton JD, Carey LA, Ahmed AA, et al. Molecular classification and molecular forecasting of breast cancer:Ready for clinical application? J Clin Oncol,2005,23(29): 7350-7360.
[32]Rodenhuis S, Bontenbal M, van Hoesel QG, et al. Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer.Ann Oncol,2006,17(4):588.
[33]Nitz UA, Gluz O, Herr A, et al. Retrospective analysis of WSG AM01 tandem high dose chemotherapy trial in high risk primary breast cancer:A hypothesis generating study.Proc Am Soc Clin Oncol,2006,24:665(Abstr).
[34]Koizumi S, Curt GA, Fine RL, et al. Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow. Journ Clin Invest,1985,75(3): 1008-1014.
[35]Saxena M, Henderson GB. Identification of efflux systems for large anions and anionic conjugates as the mediators of methotrexate efflux in L1210 cells[J]. Biochem Pharmacol, 1996,51(7):974-982.
[36]Dicker AP, Waltham MC, Volkenandt M, et al. Methotrexate resistance in an in vivo mouse tumor due to a non-active-site dihydrofolate reductase mutation[J]. Proc Natt Acad Sci USA,1993,90(24):11797-11801.
[37]Beijersbergen JR, Bernards R. Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins[J]. Biochem Biophys Acta,1996,1287(2-3):103-120.
[38]Jansen G, Pieters R. The role of impaired transport in(pre) clinical resistance to methotrexate:insights on new antifolates [J]. Drug Res Updates,1998,1(3):211-218.
[39]Moscow JA. Methotrexate transport and resistance[J]. Leuk Lymphoma,1998,30(3-4): 215-224.
[40]Xiao H, Verdier P, Fernandez N, et al. insights into the mechanism of microtubule stabilization by taxol[J]. Proc Natl Acad Sci.2006,103(27):10166-10173.
[41]Mielke. Individualized pharmacotherapy with paclitaxel [J]. Curr Opin Oncol,2007,19(6): 586-589.
[42]Swanton C, Marani M, Pardo O, et al. Regulators of mitotic arrest and ceramide metabolism am determinants of sensitivity to paclitaxel and other chemotherapeutic drugs[J]. Cancer Cell,2007,11(6):498-512.
[43]Wiesen KM, Xia S, Yang CP, et al. Wild-type class I beta-tubulin sensitizes Taxol-resistant breast adenocarcinoma cells harboring a beta-tubulin mutation[J]. Cancer Lett,2007,18,257(2):227-235.
[44]Wang Y, O Brate A, Zhou W, et al. Resistance to microtubule-stabilizing drugs involves two events:beta-tubulin mutation in one allele followed by loss of the second allele[J]. Cell Cycle,2005,4(12):1847-1853.
[45]Kavallaris M, Kuo DY, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest,1997, 100(5):1282-1293.
[46]Verdier Pinard P, Wang F, Martello L, et al. Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusingand mass spectrometry. Biochemistry,2003,42(18):5349-5357.
[47]Hari M, Yang H, Zeng C, et al. Expression of class Ⅲ beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskeleton,2003,56(1):45-56.
[48]Kamath K, Wilson L, Cabral F, et al. Beta Ⅲ-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability:J Biol Chem,2005, 280(13):12902-12907.
[49]Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase[J]. Clin Cancer Res,2000,6(4): 1322-1327.
[50]岳瑶,5-氟尿嘧啶的耐药与逆转研究进展[J].临床肿瘤学杂志,2003,8(5)：1387-1388.
[51]Kornmann M, Schwabe W, Sander S, et al. thymidylate synthase and dihydropyrimidine dehydrogenase mrna expression levels:predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil[J]. Clin Cancer Res,2003,9(9):4116-4224.
[52]Kurebayashi J, yamamoto Y, Udagawa K, et al. establishment of enzyme-linked immunosorbent assays for thymidylate synthase and dihydropyrimidine dehydrogenase in cancer tissues. Oncol Rep,2004,11(5):973-979.
[53]Li HX, Zh S, Zhang YH, et al. Expressions of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase in breast cancer and their correlations with prognosis. Zhonghua Zhong Liu Za Zhi,2004,26(11):669-672.
[54]sasaki H, Fukai I, Kiriyama M, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in thymoma [J]. Surg Today.2003,33(2):183-188.
[55]Etienne MC, cheradame S, Fischel JL, et al. Response to flourouracil therapy in cancer patients:the role of tumoral dihydropyrimidine dehydrpgenase activity[J]. J Clin Oncol, 1995,13(7):1663-1670.
[56]Terashima M, Irinoda T, Fujiwara H, et al. Roles of thymidylate synthase and dihydropyrimidine dehydrpgenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer[J]. Anticancer Res,2002,22(2A):761-768.
[57]Kralovanszky J, Koves I, Orosz Z, et al. Prognostic significance of the thymidylate biosynthetic enzymes in human colorectal tumors[J]. Oncology.2002,62(2):167-174.
[58]Matsushita S, Nitanda T, Furukawa T, et al. The effect of a thimidine phosphorylase inhibition angiogenesis and apoptosis in tumors[J]. Cancer Res,1999,59(9):1911-1916.
[59]Fukushima M, Okabe H, Takechi T, et al. Induction of thimidine phosphorylase by interferon and taxanes occurs only in human cancers cells with low thimidine phosphorylase activity[J]. Cancer Lett,2002,187(1-2):103-110.
[60]Goto H, kohno K, Sone S, et al. Interferon gamma-dependent induction of thimidine phosphorylase/platelet-derived endothelial cell growth factor through gamma-activated sequence-like element in human macrophages[J]. Cancer Res,2001,61(2):469-473.
[61]Patterson AV, Zhang H, Moghaddam A, et al. Increased sensitivity to the prodrug 5-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thimidine phosphorylase[J]. Br J Cancer,1995,72(3):669-675.
[62]Eda H, Fujimoto K, Watanabe S, et al. Cytokines induce thimidine phosphorylase expression in tumor cells and make them more susceptible to 5-deoxy-5-fluorouridine[J]. Cancer Chemother Phamacol,1993,32(5):333-338.
[63]Ambrosone CB, Sweeney C, Coles BF, et al. Polymorphism in glutathione S-transferases (GSTM1 and GSTM2) and survival after treatment for breast cancer[J]. Cancer Res,2001, 61(19):7130-7135.
[64]Howells RE, Dhar KK, Hoban PR, et al. Association between glutathione S transferase GSTP1 genotypes, GSTP1 overexpression and outcome in epithelial ovarian cancer[J]. Int J Gynecol Cancer,2004,14(2):242-250.
[65]Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance[J]. Oncogene,2003,22(47):7369-7375.
[66]Kruh GD, Belinsky MG. The MRP family of drug efflux pumps [J]. Oncogene,2003, 22(47):7537-7552.
[67]Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP(ABCG2)[J]. Oncogene,2003,22 (47):7340-7358.
[68]Sun J, He ZG, cheng G, et al. Multidrug resistence p-glycoprotein.crucial significance in drug disposition and interaction[J]. Med Sci Monit,2004,10(1):5.
[69]Ambudkar SV, Kimchi-sarfaty C, Sauna ZE, et al. P-glycoprotein from genomics to mechanism[J]. Oncogene,2003,22(47):7468.
[70]Pastan I, Gottesman M. Multiple-drug resistance in human cancer[J]. N Engl J Med,1987, 316(22):1388-1393.
[71]Lautier D, Canitrot Y, Deeley RG, et al. Multidrug resistance mediated by the multidrug resistance protein(MRP) gene[J]. Biochem Pharmacol.1996,52(7):967-977.
[72]Sharp SY, Smith V, Hobbs S, et al. Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines[J]. Br J Cancer,1998,78(2):175-180.
[73]Kool MDE, Hass M, Scheffer GI, et al. Analysis of expression of EMOAT(MRP2)、 MRP3、MRP4 and MRP5, homologues of the multidrug resistance-associated protein gene(MRP1), in human cancer cell lines[J]. Cancer Res,1997,57(8):3537-3547.
[74]Scheper RJ, Broxterman HJ, Scheffer GL, et al. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-meidiated multidrug resistance. Cancer Res,1993, 53(7):1475-1479.
[75]徐兵河,蒽环类耐药性乳腺癌的治疗策略[J].中华肿瘤杂志,2007,29(4)：241-244.
[76]Xu BH, Singh SV. Efect of buthionine sulfoximine and ethacrynic acid on cytotoxic activity of mitomycin C analogues BMY 25282 and BMY 25067. Cancer Res,1992, 52 (23):6666-6670.
[77]Xu BH, Gupta V, Singh SV. Characterization of a human bladder cancer cell line selected for resistance to mitomycin C. Int J Cancer,1994,58 (5):686-692.
[78]Airoldi M, Cattel L, Pedani F, et al. Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycine resistant/relapsed metastatic breast cancer. Acta Oncol,2003,42 (3):186-194.
[79]Maiche AG, Jekumen AP, Kaleva-Kerola J, et al. High response rate with a lower dose of paclitaxel in combination with cispahin in heavily pretreated patients with advanced breast carcinoma. Cancer,2000,88(8):1863-1868.
[80]O'shaughnessy J, Miles D, Vakelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer:phaseⅢ trial results. J Clin Oncol,2002,20 (12):2812-2823.
[81]Blum JL, Dieras V, Lo Russo PM, et al. Multicenter phaseⅡ study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer,2001,92(7):1759-1768.
1刘予生,陈建中.三苯氧胺与乳癖散结在乳腺增生中的临床应用[J].中国实用医刊,2010,37(8)：68～69.
2刘予生,刘志强,徐霓.计算机辅助设计系统在乳房再造中的实用性分析[J].河南医学研究,2009,18(4)：333～334.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |